Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance studySep 11Weekly roundup, 2 itemsadagrasibBristol Myers Squibb
BMS logs three FDA label approvals and posts results for melanoma combo trialSep 2Weekly roundup, 5 itemsadagrasibBristol Myers Squibb
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Verastem registers open-label extension study for avutometinib-defactinib in LGSOCAug 5Trial updateavutometinibdefactinib
BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registeredJul 24Weekly roundup, 6 itemsadagrasibBristol Myers Squibb
Sign inSign in